Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Takeda Pricing Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Our Pipeline
Therapeutic Areas
Patient Services & Assistance
U.S. Product List
Independent Medical Education Grants
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Corporate Responsibility
Purpose-led Sustainability
Sustainability underpins all we do at Takeda to help solve key societal challenges and create value for society.
Learn more
Patients
Patient Services and Assistance
Diversity, Equity & Inclusion in R&D
People
Diversity, Equity & Inclusion
Commitment to Community
Careers
Planet
Ethics and Compliance
Statements & Disclosures
HOME
Newsroom
US News Releases
Share:
Newsroom
US News Releases
Statements
NATPARA Updates
Global News Releases
US News Releases
Enter
All
Last 12 months
2022
2021
2020
2019
2018
2017
2016
October 2019
October 10, 2019
10/10/2019
Working Mother Names Takeda as One of the 2019 100 Best Companies
September 2019
September 25, 2019
9/25/2019
First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab
September 24, 2019
9/24/2019
Takeda Announces NATPARA® Special Use Program in the US
September 13, 2019
9/13/2019
Message about the US NATPARA Recall
September 5, 2019
9/5/2019
Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate
July 2019
July 22, 2019
7/22/2019
Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
May 2019
May 19, 2019
5/19/2019
New Exploratory Data from VARSITY Study of Vedolizumab Presented at DDW
May 19, 2019
5/19/2019
New Exploratory Data from VARSITY Study of Vedolizumab Presented at 2019 Digestive Disease Week
3
4
5
6
7
TOP
Close